Detailed reasons for the delay in submission of audited financial results for the quarter and year ended 31st March 2025 is attached.
Price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Indrayani Biotech has informed the BSE that it will not meet the 30 May 2025 deadline for submitting its audited standalone and consolidated financial results for the quarter and year ended 31 March 2025. The company says the delay is because consolidating results from its subsidiaries is taking longer than expected, and both internal and external audit processes are still ongoing. The board meeting to approve the results has been rescheduled to Monday, 9 June 2025, and the results will be filed with the stock exchange on the same day. The trading window for insiders remains closed until 48 hours after the results are declared. This filing is essentially an administrative intimation explaining the delay, not the actual results themselves.
Shareholders will have to wait about 10 extra days for the full-year FY25 numbers. While the delay is administrative in nature, repeated postponements in audit completion can dent investor confidence and signal weaker financial controls.